Women and lung cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 2, 2006, Pages

  Novello, S ^a   Baldini, E ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UO Oncologia Medica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOCHROME P450 1A1; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ESTROGEN; GEFITINIB; GLUTATHIONE TRANSFERASE M1; MESSENGER RNA; MITOMYCIN; PROTEIN P53; VINDESINE;

AGE DISTRIBUTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHROMOSOME ABERRATION; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DNA REPAIR; DOWN REGULATION; EPIDEMIC; FEMALE; GENE CLUSTER; GENE DELETION; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; INTERMETHOD COMPARISON; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; UPREGULATION; WOMEN'S HEALTH; X CHROMOSOME; X CHROMOSOME INACTIVATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; PROGNOSIS; PROTEIN KINASE INHIBITORS; RISK FACTORS; SEX DISTRIBUTION; SMOKING; SURVIVAL ANALYSIS;

EID: 33645814030     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj932     Document Type: Article

References (33)

1. Patel JD, Bach PB, Kris MG et al. Lung Cancer in US women: A contemporary epidemic. J Am Med Assoc 2004; 291: 1763-1768.
2. Osann K, Anton-Culver H, Kurosaki T et al. Sex differences in lung cancer-risk associated with cigarette smoking. Int J Cancer 1993; 54: 44-48.
3. Travis WD, Lubin J, Ries L et al. United States Lung carcinoma incidence trends: Declining for most histologic types among males, increasing among females. Cancer 1996; 77: 2464-2470.
4. Radzikowska E, Giaz P, Roszkowski K et al. Lung cancer in women: Age, smoking, histology, performance status, stage, initial treatment and survival. Population based study of 20561 cases. Ann Oncol 2002; 13: 1087-1093.
5. Risch HA et al. Are female smokers at higher risk for lung cancer than male smokers? A case-control analisys by histological type. Am J Epidemiol 1993; 138: 281-293.
6. Zhang EA et al. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996; 88: 183-192.
7. Bain C et al. Lung cancer rates in men na dwomen with comparable histories of smoking. J Natl Cancer Inst 2004; 96: 826-834.
8. Kure EH. p53 mutations in lung tumors: Relationship to gender and lung DNA adduct levels. Carcinogenesis 1996; 17: 2201-2205.
9. Mollerup S et al. Sex differences in lung CYP1A1 expression and DNA adduca levels among lung cancer patients. Cancer Res 1999; 59: 3317-3320.
10. Dresler C et al. Gender differences in genetic susceptibility for lung cancer. Lung Cancer 2000; 30: 153-157.
11. Nelson HH et al. Implications and prognostic value of K-ras mutations for early-stage lung cancer in women. J Natl Cancer Inst 1999; 91: 2032-2038.
12. Seigfried JM. Oestrogen in lung cancer. Lancet Oncol 2001; 2: 506-513.
13. Stabile LP et al. Human non small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002; 62: 2141-2150.
14. Taioli E, Wynder EL. Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994; 86: 869-870.
15. Janne PA et al. Epidermal growth factor receptor mutations in NSCLC:iMplications for treatment and tumor biology. J Clin Oncol 2005; 23: 3227-3234.
16. Ouellette D, Desbiens G, Emond C et al. Lung cancer in women compared with men: Stage, treatment and survival. Ann Thorac Surg 1998; 66: 1140-1144.
17. Moore R, Doherty D, Chamberlain R et al. Sex differences in survival in non-small cell lung cancer patients 1974- 1998. Acta Oncol 2004; 43: 57-64.
18. Visual AL, Williams BA, Nichols FC III et al. Gender differences in non-small cell lung cancer survival. An analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Sung 2004; 78: 209-215.
19. dePerrot M, Licker M, Bouchardy C et al. Sex differences in presentation, management and prognosis of patients with non small cell carcinoma. J Thorac Cardiovasc Surg 119: 21-26, 2000.
20. Ferguson MK, Wang J, Hoffman PC. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg 2000; 69: 245-250.
21. Alexiou C, Onyeaka CV, Beggs D et al. Do Women live longer following lung resection for carcinoma? Eur J Cardiothorac Surg 2002; 21: 319-325.
22. Giorgio V. Scagliotti on behalf of the Adjuvant Lung Cancer Project Italy/European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. The ALPI Trial: The Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer. Clin Cancer Res 2005; 11 (13 Pt 2): 5011s-5016s.
23. Albain KS, Rusch VW, Crowley JJ. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13: 1880-1992.
24. Albain KS, Crowley JJ, LeBlanc M et al. Survival determinants in extensive-stage non-small cell lung cancer: The Southwest Oncology Group Experience. Am J Clin Oncol 1991; 9: 1618-1626.
25. Paesmans M, Sculier JP, Libert G. Prognostic factors for survival in advanced non-small cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol 1995; 13: 1221-1230.
26. Johnson BE, Steinberg SM, Phelps R et al. Female patients with small cell lung cancer liver longer than male patients. Am J Med 1988; 85: 194-196.
27. Albain KS, Crowley JJ, LeBlanc M et al. Determinants of improved outcome in small-cell lung cancer: An analysis of the 2580-patient Southwest Oncology Group database. Am J Clin Oncol 1990; 8: 1563-1574.
28. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinnib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
29. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. J Am Med Assoc 2003; 290: 2149-2158.
30. Guillermo PJ, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
31. West H, Franklin WA, Gumerlock PH et al. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126. Proc Am Soc Clin Oncol 2004; 22: 145 (Abstr 7014).
32. O'Connel J, Kris MG, Adak S et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell cancer treated with combination therapy. J Clin Oncol 1986; 4: 1604-1614.
33. Mitsudomi T, Tateishi M, Oka T et al. Longer survival after resection of non-small cell lung cancer in Japanese women. Ann Thorac Surg 1989; 48: 639-642.